Portage Biotech Inc. announced the appointment of Dr. Ian Walters as an independent Director of the company and a member of Audit and Compensation committee effective August 1, 2016. Portage now has six Directors. Ian Walters, M.D., M.B.A. is an experienced life science entrepreneur who has helped found and launched several life science companies. He is currently the founder and CEO of SalvaRx and iOx Therapeutics. He is also the Chief Medical Officer for Intensity Therapeutics. Dr. Walters has led drug development teams in several therapeutic areas and contributed to bringing 4 blockbuster products to market, including Opdivo®, Yervoy®, and Velcade®. While Dr. Walters worked at BMS, he managed physicians overseeing the international development of more than 8 oncology compounds as well as biomarker and companion diagnostic work. He also was a core member of BMS's Strategic Transactions Group evaluating and executing licensing agreements, mergers and acquisitions, and clinical collaborations. Before entering the private sector, Dr. Walters was a lead investigator at the Rockefeller University and initiated cutting edge immunology research to understand the mechanism of action of several compounds. Dr. Walters received his MD from the Albert Einstein College of Medicine and an MBA from the Wharton School of the University of Pennsylvania.